Celcuity (NASDAQ:CELC) Receives News Impact Rating of 0.09

News coverage about Celcuity (NASDAQ:CELC) has trended somewhat positive this week, according to Accern Sentiment. Accern ranks the sentiment of news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Celcuity earned a coverage optimism score of 0.09 on Accern’s scale. Accern also gave media headlines about the company an impact score of 48.322983961174 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Separately, Craig Hallum began coverage on Celcuity in a report on Monday, October 16th. They issued a “buy” rating for the company.

Celcuity (NASDAQ:CELC) traded up 1.43% on Friday, hitting $16.34. The company had a trading volume of 6,491 shares. The firm has a 50-day moving average price of $14.27 and a 200-day moving average price of $14.27. Celcuity has a 12-month low of $11.10 and a 12-month high of $16.97. The firm’s market capitalization is $158.86 million.

WARNING: “Celcuity (NASDAQ:CELC) Receives News Impact Rating of 0.09” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2017/10/28/celcuity-celc-receiving-somewhat-positive-news-coverage-study-shows.html.

Celcuity Company Profile

Celcuity, Inc is a cellular analysis company. The Company is focused on discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. The Company’s proprietary CELx diagnostic platform uses a patient’s living tumor cells to identify the specific abnormal cellular process driving a patient’s cancer and the targeted therapy that best treats it.

Receive News & Ratings for Celcuity Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply